ATHRO 2

 Directory of registries
ATHRO 2

Terminated survey of patient compliance and the administration of antiplatelet therapy in patients with acute coronary syndrome who have been hospitalised in PCI centres all over the Czech Republic.

 start of the project: 04/2014

 end of the project: 02/2015

Cardiovascular disease is the leading cause of death in developed countries, and it is expected to become the leading cause of death in developing countries by 2020. Coronary heart disease (CHD) is one of the most frequent cardiovascular diseases, and it is characterised by high mortality and morbidity rates. The clinical manifestation of coronary heart disease involves silent myocardial ischaemia, stable angina pectoris, acute coronary syndromes, heart failure, and sudden cardiac death. Patients with acute coronary syndrome (ACS) represent a significant proportion of CHD patients.

The term “acute coronary syndrome” involves ST segment elevation myocardial infarction (STEMI), non-ST segment elevation myocardial infarction (NSTEMI), and unstable angina pectoris.

In the Czech Republic, ACS patients are referred to PCI centres, where a subsequent therapy is administered (depending on the time period since the onset of difficulties and on the type of coronary syndrome), including a potential percutaneous coronary intervention (PCI) and a relevant pharmacotherapy. Antiplatelet therapy is an important part of the overall therapy. Antiplatelet therapy involves the administration of acetylsalicylic acid (which is given even before the patient’s hospitalisation), clopidogrel (inhibitor of the P2Y12 receptor), and new P2Y12 inhibitors such as prasugrel and ticagrelor, as recommended by the latest guidelines. However, this combination of drugs is prescribed no sooner than 12 months after the onset of coronary syndrome. After the patient’s discharge from hospital, therapy is carried out on an outpatient basis; and patient compliance with the treatment regimen is of key importance for a successful therapy.

The main objective of this survey was to describe patients with acute coronary syndrome (ACS) after their discharge from PCI centres, changes in their lifestyle, compliance with the prescribed therapy, and the overall trajectory of patient treatment on a dataset of 1000 patients followed up in the Czech Republic in the period 2014–2015. The survey did not evaluate treatment safety nor treatment effectiveness.

  • Expert guarantor: Prof. Petr Widimský, M.D., FESC, Pavel Svítil, M.D.
  • Funding: AstraZeneca Czech Republic, Ltd.
  • Partners: dozens of outpatient cardiology clinics all over the Czech Republic